Lantheus Holdings News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.11.24	Lantheus To Repurchase Up To $250 Mln Of Shares (RTTNews)
15.07.24	Lantheus Acquires Meilleur Technologies - Quick Facts (RTTNews)
21.06.24	Radiopharm Theranostics Secures Up To A$18 Mln Investment From Lantheus (RTTNews)
04.03.24	Lantheus Holdings Announces Expanded Indication For DEFINITY (RTTNews)
22.02.24	Lantheus Holdings Gains On Announcement Of Upbeat Q4 Report (RTTNews)
26.01.24	Lantheus Sued By Novartis Entities For Patent Infringement (RTTNews)
23.01.24	Lantheus Stock Falls 4% Over Announcement Of CEO Succession Plan (RTTNews)
23.01.24	Lantheus Names Brian Markison CEO (RTTNews)
11.01.24	Lantheus: FDA Accepts For Filing ANDA For Generic Version Of LUTATHERA (RTTNews)
18.12.23	Lantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study Results (RTTNews)
07.10.22	Pre-market Movers: ATXI, NVIV, PRTC, IVA, ARBK… (RTTNews)
07.10.22	Targa Resources To Replace Nielsen In S&P 500 (RTTNews)
07.10.22	Targa Resources Set to Join S&P 500; Lantheus Holdings to Join S&P MidCap 400; Payoneer Global to Join S&P SmallCap 600 (PR Newswire)
13.09.22	GE Healthcare, Lantheus: Trial Finds Flurpiridaz PET Radiotracer Could Improve CAD Detection (RTTNews)
07.06.22	Lantheus Having A Banner Year In 2022 (RTTNews)
03.06.22	Pre-market Movers: GTIM, BTMD, SGHC, JOAN, OKTA… (RTTNews)
26.05.22	Pre-market Movers: NTNX, WKME, SNOW, ISPC, NNVC… (RTTNews)
28.06.21	Pre-market Movers: NTLA, ABUS, ATOS, GTEC... (RTTNews)
14.06.21	Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting (Businesswire)
27.05.21	FDA Approves Lantheus Holdings' Imaging Agent For Prostate Cancer (RTTNews)
27.05.21	Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer (Businesswire)
21.05.21	Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting (Businesswire)
20.05.21	Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
20.05.21	Will The Regulatory Catalyst Impact These 3 Small-cap Pharma Stocks This Month? (RTTNews)
04.05.21	Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results (Businesswire)
03.05.21	EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe (Businesswire)
20.04.21	Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time (Businesswire)
07.04.21	Lantheus Expands R&D Leadership Team with Key New Hires (Businesswire)
01.04.21	Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel (Businesswire)
30.03.21	Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria (Businesswire)
22.03.21	Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021 (Businesswire)
01.03.21	Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies (Businesswire)
25.02.21	Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
12.02.21	Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference (Businesswire)
11.02.21	Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time (Businesswire)
04.02.21	Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting (Businesswire)
12.01.21	Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S. (Businesswire)
09.12.20	Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent (Businesswire)
03.12.20	Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement (Businesswire)
24.11.20	Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference (Businesswire)
19.11.20	After-Hours Market: Nuance, Sonos, Aquestive, Lantheus Gain; GoPro Slips (RTTNews)
18.11.20	Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature (Businesswire)
13.11.20	Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform (Businesswire)
09.11.20	CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences (Businesswire)
05.11.20	Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results (Businesswire)
04.11.20	Lantheus Holdings to Present at November 2020 Investor Conferences (Businesswire)
29.10.20	Lantheus Enters into Strategic Collaboration with Insightec for Use of Microbubbles in Combination with MR-Guided Focused Ultrasound for Treatment of Glioblastoma and Neurodegenerative Conditions (Businesswire)
22.10.20	Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8:00 a.m. Eastern Time (Businesswire)
08.10.20	Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress (Businesswire)
30.09.20	Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Lantheus Holdings Inc

Aktien Top/Flop

Meistgelesene Nachrichten